Brought to you by 
Idenix nets $165.9mm via FOPO
07 Aug 2012
Executive Summary
Infectious disease-focused Idenix Pharmaceuticals Inc. has netted $165.9mm through the follow-on public offering of 22mm common shares at $8.00 each. The company will use a portion of the proceeds for ongoing development activities, including combination Phase IIb trials of IDX184 with IDX719 for hepatitis C, and proof-of-concept and Phase IIa studies of IDX19368 in combination with ribavirin, also for HCV.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idenix nets $165.9mm via FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice